Benzinga

España
Italia
대한민국
日本
Français
Benzinga Edge
Benzinga Research
Benzinga Pro

  • Get Benzinga Pro
  • Data & APIs
  • Events
  • Premarket
  • Advertise
Contribute
España
Italia
대한민국
日本
Français

Benzinga

  • Premium Services
  • Financial News
    Latest
    Earnings
    Guidance
    Dividends
    M&A
    Buybacks
    Interviews
    Management
    Offerings
    IPOs
    Insider Trades
    Biotech/FDA
    Politics
    Healthcare
    Small-Cap
  • Markets
    Pre-Market
    After Hours
    Movers
    ETFs
    Options
    Cryptocurrency
    Commodities
    Bonds
    Futures
    Mining
    Real Estate
    Volatility
  • Ratings
    Analyst Color
    Downgrades
    Upgrades
    Initiations
    Price Target
  • Investing Ideas
    Trade Ideas
    Long Ideas
    Short Ideas
    Technicals
    Analyst Ratings
    Analyst Color
    Latest Rumors
    Whisper Index
    Stock of the Day
    Best Stocks & ETFs
    Best Penny Stocks
    Best S&P 500 ETFs
    Best Swing Trade Stocks
    Best Blue Chip Stocks
    Best High-Volume Penny Stocks
    Best Small Cap ETFs
    Best Stocks to Day Trade
    Best REITs
  • Money
    Investing
    Cryptocurrency
    Mortgage
    Insurance
    Yield
    Personal Finance
    Forex
    Startup Investing
    Real Estate Investing
    Prop Trading
    Credit Cards
    Stock Brokers
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
Unusual Options Activity Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Perfect Stock Portfolio
Easy Income Portfolio
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Screeners
Stock Screener
Top Momentum Stocks
Top Quality Stocks
Top Value Stocks
Top Growth Stocks
Compare Best Stocks
Best Momentum Stocks
Best Quality Stocks
Best Value Stocks
Best Growth Stocks
Connect With Us
facebookinstagramlinkedintwitteryoutubeblueskymastodon
About Benzinga
  • About Us
  • Careers
  • Advertise
  • Contact Us
Market Resources
  • Advanced Stock Screener Tools
  • Options Trading Chain Analysis
  • Comprehensive Earnings Calendar
  • Dividend Investor Calendar and Alerts
  • Economic Calendar and Market Events
  • IPO Calendar and New Listings
  • Market Outlook and Analysis
  • Wall Street Analyst Ratings and Targets
Trading Tools & Education
  • Benzinga Pro Trading Platform
  • Options Trading Strategies and News
  • Stock Market Trading Ideas and Analysis
  • Technical Analysis Charts and Indicators
  • Fundamental Analysis and Valuation
  • Day Trading Guides and Strategies
  • Live Investors Events
  • Pre market Stock Analysis and News
  • Cryptocurrency Market Analysis and News
Ring the Bell

A newsletter built for market enthusiasts by market enthusiasts. Top stories, top movers, and trade ideas delivered to your inbox every weekday before and after the market closes.

  • Terms & Conditions
  • Do Not Sell My Personal Data/Privacy Policy
  • Disclaimer
  • Service Status
  • Sitemap
© 2026 Benzinga | All Rights Reserved
mark cuban
September 3, 2025 10:55 PM 3 min read

Mark Cuban Says Drug Companies Intentionally Create Shortages. Even Pediatric Cancer Drugs Are Manipulated To Jack Up Prices

by Adrian Volenik
Follow

ArticleFeaturedTickersList12345!!!

Billionaire entrepreneur Mark Cuban claimed pharmaceutical companies intentionally create drug shortages—including for life-saving medications like pediatric cancer drugs—just to boost profits.

Drug Shortages Aren’t Accidental

Cuban, who launched the online pharmacy Cost Plus Drugs in 2022, said he was shocked by how broken the current health care pricing system is. “When you think about health care, no one looks at the financial side and says, ‘This is the way it should work. It’s perfect,'” he said on the recent “Equity” podcast.

Don't Miss:

  • The same firms that backed Uber, Venmo and eBay are investing in this pre-IPO company disrupting a $1.8T market — and you can too at just $2.90/share.
  • Kevin O'Leary Loves ‘Wonderful Recurring Cash Flows' — These Small Industrial Assets Deliver Just That

He explained that many essential generic medications go into short supply not by accident but by design. “Believe it or not, in this day and age, there are things like pediatric cancer drugs, Pitocin, sterile water, this long list of drugs I can’t even pronounce… they go in short supply because the manufacturers want them to go on short supply,” he said. “That’s how they jack up the price.”

To combat this, Cuban said Cost Plus Drugs built a manufacturing facility in Dallas that can quickly switch to producing critical drugs in shortage. “We can turn over to a new drug in four hours and ship it out to hospitals,” he said.

Since launching, Cuban’s company has never hidden its pricing. “We released our first price list with 111 drugs Jan. 19, 2022. Here we are three and a half years later. No other company has put out a price list for all of their medications.”

Trending: From Chipotle to Red Bull, Top Brands Are Already Building With Modern Mill's Tree-Free Wood Alternative — Here's How You Can Invest Too

AI Could Be A Job Creator, Not A Job Killer

Cuban also shared his optimism about artificial intelligence, especially for young people entering the workforce. He believes AI skills are becoming one of the biggest equalizers in the job market.

“If you’re confident and capable of applying that to businesses—whether it’s a shoe store, a technology company, whatever—they need to hire you,” he said.

See Also: Wealth Managers Charge 1% or More in AUM Fees — Range's AI Platform Does It All for a Flat Fee (and Could Save You $10,000+ Annually). Book Your Demo Today.

Independence Matters In Disrupting Big Industries

For Cuban, the key to taking on powerful industries is independence. “If I were 25 and starting this business, I probably would work through the pharmacy benefit managers because that’s where the money is,” he said. “But if we had gone that direction, like Amazon (NASDAQ:AMZN) did, they’re beholden to the big pharmacy benefit managers.”

His advice to founders trying to disrupt entrenched industries: “You’ve got to be quick or you’re going to be dead. And so you’ve got to be lean, mean.”

Read Next: ‘Scrolling To UBI' — Deloitte's #1 fastest-growing software company allows users to earn money on their phones. You can invest today for just $0.30/share.

Image: Imagn Images

Market News and Data brought to you by Benzinga APIs

© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.


Posted In:
Newsnews accessStartups Access
AMZN Logo
AMZNAmazon.com Inc
$233.590.26%
Overview

“Kids aren’t getting jobs coming out of school. I think that’s going to change immediately for anybody who’s confident and comfortable with AI,” he said. Cuban noted that millions of small and mid-sized businesses are struggling to integrate AI, creating a huge opportunity for students and recent grads.

AMZN Logo
AMZNAmazon.com Inc
$233.590.26%
Overview
Comments
Loading...